RCM
RXRX icon

RA Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

RA Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,725,096
Closed -$52.2M – 96
2024
Q4 		$52.2M Sell
7,725,096
-7,659,519
-50% -$51.5M 0.7% 29
2024
Q3 		$101M Hold
15,384,615
– – 1.17% 25
2024
Q2 		$115M Buy
+15,384,615
New +$134M 1.53% 17

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

RA Capital Management's RXRX Position: Q1 2025 in Review

RA Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 7,725,096 shares — an estimated $52.2M sold.

RA Capital Management first reported a position in RXRX in Q2 2024 and held it in 3 quarters. The position peaked at $115M in Q2 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • RA Capital Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • RA Capital Management sold 7,725,096 Recursion Pharmaceuticals shares in Q1 2025, an estimated $52.2M.
  • RA Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • RA Capital Management's Recursion Pharmaceuticals position peaked at $115M in Q2 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.